Inhibrx Achieves Progress on Challenging Immunotherapy Target

Inhibrx has claimed a key milestone in targeting a long-sought immunotherapy mechanism that has historically stumped drug developers.

Addressing the difficulty of this achievement, Inhibrx Chief Executive Officer Mark Lappe noted that advancing research in this area has been an uphill battle, citing the numerous past failures across the industry.